EAN 2022 | Final results of DUOGLOBE: real-world evidence for LGIC in advanced Parkinson’s disease
K. Ray-Chaudhuri, MD, DSc, FRCP, FEAN, King’s College London, London, UK, presented the final analysis of the DUOGLOBE study (NCT02611713) at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria. The study was a two-year, international prospective registry of real-life data collected from patients with advanced Parkinson’s disease (PD), treated with intrajejunal levodopa-carbidopa infusion in routine clinical practice. Several clinical trials of levodopa-carbidopa intestinal gel (LGIC) have documented its efficacy against motor and non-motor symptoms in advanced stages of disease, but long-term data on its real-world use is limited. In DUOGLOBE, long-term motor function and non-motor symptoms (e.g. quality of life) were analyzed over the two-year follow-up, in addition to data on caregiver stress. The data showed sustained and consistent improvements in motor function and non-motor function, such as sleep, mood, pain, and gastrointestinal symptoms across two years. Additionally, caregivers’ strain and patients’ quality of life improved.
Transcript
DUOGLOBE is a prospective registry of real-life data collection of patients who are treated with intrajejunal levodopa infusion. This study collected data over 2 years in many centers around the world to look at how people who go on this infusion therapy do with their motor, but most importantly, also non-motor issues, their quality of life. We also collected data on caregivers stress. So, if a patient with Parkinson’s gets treatment, what happens to the caregivers? It’s a mixture of all of those data, which was the final data from which was presented in this meeting here today...
DUOGLOBE is a prospective registry of real-life data collection of patients who are treated with intrajejunal levodopa infusion. This study collected data over 2 years in many centers around the world to look at how people who go on this infusion therapy do with their motor, but most importantly, also non-motor issues, their quality of life. We also collected data on caregivers stress. So, if a patient with Parkinson’s gets treatment, what happens to the caregivers? It’s a mixture of all of those data, which was the final data from which was presented in this meeting here today.
The data shows a sustained and consistent improvement in the motor function, but also non-motor functions, particularly sleep, aspects of sleep, aspects of gastrointestinal symptoms, mood, and pain, all improve and is sustained at 2 years. But not just that, caregiver strain also improves and patient’s quality of life improves. So this real-life data, which is beyond the typical population a clinical trial focuses on, really gives us more evidence of the fantastic efficacy of this treatment.
Read more...
